{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05364684",
            "orgStudyIdInfo": {
                "id": "2022P001057"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease",
            "officialTitle": "The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study",
            "therapeuticArea": [
                "Other",
                "Gastroenterology"
            ],
            "study": "the-impact-of-ibutamoren-on-nonalcoholic-fatty-liver-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-03",
            "studyFirstSubmitQcDate": "2022-05-03",
            "studyFirstPostDateStruct": {
                "date": "2022-05-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-24",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Laura Dichtel, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS)."
        },
        "conditionsModule": {
            "conditions": [
                "NAFLD",
                "Nonalcoholic Fatty Liver",
                "NASH - Nonalcoholic Steatohepatitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Open-label study with historical controls.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Open-label Treatment",
                    "type": "OTHER",
                    "description": "Open-label study of oral LUM-201 (ibutamoren mesylate) 25mg daily in otherwise healthy adults with BMI \u226525 kg/m2 and histologic or radiologic diagnosis of NAFLD.",
                    "interventionNames": [
                        "Drug: LUM-201"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LUM-201",
                    "description": "LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.",
                    "armGroupLabels": [
                        "Open-label Treatment"
                    ],
                    "otherNames": [
                        "Ibutamoren Mesylate"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Intrahepatic lipid content (IHL, %)",
                    "description": "Change in intrahepatic lipid content (IHL, %) as measured by proton magnetic resonance spectroscopy (1H-MRS).",
                    "timeFrame": "6 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Hepatic inflammation and fibrosis by LiverMultiScan corrected T1 (cT1) score",
                    "description": "Change in hepatic inflammation and fibrosis by LiverMultiScan cT1. Higher values indicate more severe combined inflammation and fibrosis (normal range 633-794 ms)",
                    "timeFrame": "6 Months"
                },
                {
                    "measure": "Alanine aminotransferase (ALT)",
                    "description": "Change in ALT",
                    "timeFrame": "6 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 21-60yo and generally healthy\n2. BMI \u2265 25 kg/m2\n3. Radiographic or histologic diagnosis of NAFLD / NASH\n4. Insulin-like growth factor-1 (IGF-1) level \\<3rd quartile of normal for age\n\nExclusion Criteria:\n\n1. Contraindications to MRI imaging\n2. Diabetes mellitus or use of diabetes medications\n3. History of cancer, significant renal disease, decompensated or unstable cardiovascular disease\n4. Cirrhosis or known liver disease other than NAFLD\n5. Pregnancy or breastfeeding\n6. Known pituitary or hypothalamic disease affecting the growth hormone axis\n7. Chronic use of drugs causing hepatic steatosis in the past 12 months (chronic oral steroids, methotrexate, tamoxifen)\n8. Treatment with medications that may interact with LUM-201 (ibutamoren mesylate)",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Laura E. Dichtel, MD, MHS",
                    "role": "CONTACT",
                    "phone": "617-726-3870",
                    "email": "ldichtel@mgh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Laura E. Dichtel, MD, MHS",
                    "affiliation": "Massachusetts General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Laura E Dichtel, MD",
                            "role": "CONTACT",
                            "phone": "617-724-3870",
                            "email": "ldichtel@partners.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Fatty Liver",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Nonalcoholic Fatty Liver",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Fatty Liver",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M1985",
                    "name": "Secretagogues",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}